Patent · US Expired

Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy

US6562319B2 · kind B2 · utility

38Cited by

2References

40Claims

0Family size

Assignees

Inventors

Eyal Mishani · Mevaseret Tsiyon, IL
Iris Ben-David · Ashdod, IL
Yulia Rozen · Jerusalem, IL
Gluseppina Ortu · Jerusalem, IL
Alexander Levitzki · Melrose, US

Key dates

Filing date	Mar 12, 2001
Grant date	May 13, 2003
Priority date	—
Expiry date	Jun 14, 2021

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.